Company Directory - Genmab A/S
Company Details - Genmab A/S
Genmab A/S
WebsiteCopenhagen, Denmark
Genmab A/S is a biotechnology company specializing in the creation and development of innovative antibody therapeutics for the treatment of cancer.
CCI Score
CCI Score: Genmab A/S
2.36
Latest Event
Genmab Disclosed Lobbying Activity in Q4 2024
Genmab A/S disclosed $60,000 spent on lobbying during Q4 2024, targeting healthcare policies including prescription drug pricing, the Inflation Reduction Act implementation, and Medicare/Medicaid issues. This activity raises concerns about the company leveraging corporate influence to sway public policy in its favor.
Take Action
So what can you do? Support Genmab by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
OBJECTOR
Genmab A/S is currently rated as an Objector.
Latest Events
- DEC312024
Genmab A/S disclosed $60,000 spent on lobbying during Q4 2024, targeting healthcare policies including prescription drug pricing, the Inflation Reduction Act implementation, and Medicare/Medicaid issues. This activity raises concerns about the company leveraging corporate influence to sway public policy in its favor.
-40
Political Contributions and Lobbying Efforts
March 26
The disclosure of $60,000 in lobbying expenditures by Genmab in Q4 2024 is indicative of efforts to influence key healthcare policies such as prescription drug pricing and Medicare/Medicaid issues. From an anti-fascist perspective, this use of political lobbying raises red flags as it suggests the company may be seeking to shape public policy in a way that benefits its business interests, potentially at the expense of public welfare.
Lobbying Update: $60,000 of GENMAB lobbying was just disclosed
- JAN012024
Genmab’s comprehensive corporate responsibility strategy—emphasizing sustainability, patient care, charitable giving, and strict adherence to international sanctions and export controls—reflects positive practices that stand in opposition to the authoritarian tactics seen in other corporate models.
+80
Public and Political Behavior
March 26
Under Public and Political Behavior, Genmab demonstrates strong adherence to ethical standards by ensuring compliance with international economic sanctions and export controls, and by positioning its policies to support patient care and community welfare. Such practices contrast with the political manipulation and erosion of democratic values seen in more authoritarian-linked corporate behaviors.
+85
Business Practices and Ethical Responsibility
March 26
Within Business Practices and Ethical Responsibility, Genmab’s initiatives—such as significant investments in community projects, charitable giving, support for healthcare, environmental sustainability efforts including tree planting, and promotion of STEM education—demonstrate robust ethical behavior that undermines the broader structures fueling authoritarianism.
- JAN012024
Genmab spent $480,000 on lobbying activities in 2024, indicating a significant effort to influence policy-making processes. Such corporate political spending raises concerns about undermining democratic accountability and contributing to an environment conducive to authoritarian practices.
-30
Political Contributions and Lobbying Efforts
March 26
The reported $480,000 lobbying expenditure in 2024 demonstrates Genmab’s active engagement in influencing political decisions. From an anti-fascist perspective, such substantial investment in lobbying can be seen as a strategy to shape policy in ways that may erode democratic norms and empower authoritarian practices.
Alternatives
Corporation
3.48
Corporation
0.00
Corporation
-43.74
Kenilworth, United States
2.89
New Haven, USA
-38.83
Corporation
2.31
Corporation
1.66
Corporation
1.00
Bagsværd, Denmark
16.06
Belgium (Ghent), Belgium
79.03
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 541712
- Research and Development in the Physical, Engineering, and Life Sciences (Biotechnology)
- 541711
- Research and Development in Biotechnology